Loading
An editorial accompanying the gynaecological review: repurposing is legitimate and early trials deserve support, but no major oncology organisation endorses ivermectin for cancer and patients should not forgo proven treatment for it.
The editorial describes drug repurposing as a sound strategy whose usual failure mode is that agents active in cell culture or mice do not deliver clinical benefit in randomised trials (Straughn editorial 2025). It states that no major oncology organisations, including ASCO, SGO or NCCN, currently endorse ivermectin for cancer treatment, that the clinical evidence is not sufficient to support its use, and that ivermectin used outside approved dosing carries real risks of toxicity and drug interactions (Straughn editorial 2025). It welcomes the early-phase trials now under way and asks the oncology community to resist leaping ahead of the science (Straughn editorial 2025).
A measured position a patient can take to their oncologist: the drug is being tested properly, and until those tests report, it is not a treatment.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Systematic drug repurposing, Ivermectin.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin.